Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
José M. Vicencio, Rachel Evans, R. Green, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 21

Showing 21 citing articles:

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
Georgia Gomatou, Nikolaos Syrigos, Ηλίας Κοττέας
Cancers (2023) Vol. 15, Iss. 3, pp. 841-841
Open Access | Times Cited: 70
Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy
Yongjuan Li, Xinyan Li, Jinmeng Yi, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 19
Closed Access | Times Cited: 33
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
Shanshan Chen, Jingyi Tang, Fen Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
The cGAS-STING pathway: a therapeutic target in diabetes and its complications
Wenjie He, Xingrui Mu, Xingqian Wu, et al.
Burns & Trauma (2024) Vol. 12
Open Access | Times Cited: 14
Integrating network pharmacology and experimental validation to explore the potential mechanism by which resveratrol acts on osimertinib resistance in lung cancer
Yu Xin, Yuan Yao, Haiwen Zhou, et al.
Oncology Letters (2025) Vol. 29, Iss. 4, pp. 1-9
Open Access | Times Cited: 1
Role of STING in the treatment of non-small cell lung cancer
Wenhua Tang, Wenjie Zhou, Mei Ji, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Emerging importance of HER3 in tumorigenesis and cancer therapy
Joan T. Garrett, Salomon Tendler, Wasim Feroz, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
Kimio Yonesaka, Takashi Kurosaki, Junko Tanizaki, et al.
Cells (2025) Vol. 14, Iss. 6, pp. 447-447
Open Access
Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
Daoan Cheng, Kele Ge, Xue Yao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Label-free nanoscale mapping of intracellular organelle chemistry
George E. Greaves, Darya Kiryushko, Holger W. Auner, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 9
The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 7
Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin
Yali Wu, Lili Chen, Jian Chen, et al.
Drug Metabolism and Disposition (2022) Vol. 51, Iss. 1, pp. 8-16
Closed Access | Times Cited: 12
Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma
Weisong Li, Chao Zheng, Xi Xu, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate
Sandra Bibbò, Emily Capone, Giulio Lovato, et al.
Journal of Controlled Release (2024) Vol. 374, pp. 171-180
Open Access | Times Cited: 2
The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas
Jinhai Deng, Teng Pan, Dan Wang, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 9, pp. 2080-2108
Closed Access | Times Cited: 1
Griffithazanone A, a sensitizer of EGFR-targeted drug in Goniothalamus yunnanensis for non-small cell lung cancer
Ting Xiao, Yuxin Zhu, Liang Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 19, pp. e38489-e38489
Open Access | Times Cited: 1
Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy
Yurui Zhang, Yudi Wang, Peizheng Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors
Margaret E. Larsen, Hui Lyu, Bolin Liu
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2023) Vol. 1, Iss. 1, pp. 11-17
Open Access | Times Cited: 2
Label-free nanoscale mapping of intracellular organelle chemistry
George E. Greaves, Darya Kiryushko, Holger W. Auner, et al.
Research Square (Research Square) (2023)
Open Access
Chemotherapeutic regulation of the ROS/MondoA-dependent TXNIP/GDF15 axis; and derivation of a new organoid metric as a predictive biomarker
Jinhai Deng, Teng Pan, Yourae Hong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
The proto-oncogene c-Src phosphorylates cGAS to reduce DNA binding and activation
William Dunker, Shivam A. Zaver, Cameron J. Howard, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top